Results 51 to 60 of about 5,850,068 (304)

Trained Immunity as a Trigger for Atherosclerotic Cardiovascular Disease—A Literature Review

, 2022
Atherosclerosis remains the leading cause of cardiovascular diseases and represents a primary public health challenge. This chronic state may lead to a number of life-threatening conditions, such as myocardial infarction and stroke.
Małgorzata Kazberuk, Kazberuk, Małgorzata, Małgorzata Chlabicz, Karol Kamiński, Eljaszewicz, Andrzej, Natalia Anna Zieleniewska, Chlabicz, Małgorzata, Zieleniewska, Natalia Anna, Kamiński, Karol, Andrzej Eljaszewicz   +9 more
core   +1 more source

Cardiovascular magnetic resonance in carotid atherosclerotic disease [PDF]

, 2009
Atherosclerosis is a chronic, progressive, inflammatory disease affecting many vascular beds. Disease progression leads to acute cardiovascular events such as myocardial infarction, stroke and death.
Ferguson Marina S, Chen Huijun, Gador Canton, Li Rui, Huijun Chen, Hatsukami Thomas S, William S Kerwin, Canton Gador, Marina S Ferguson, Li Dong, Chun Yuan, Dong Li, Jinnan Wang, Thomas S Hatsukami, Rui Li, Kerwin William S, Yuan Chun, Wang Jinnan   +17 more
core   +1 more source

Framingham and American College of Cardiology/American Heart Association Pooled Cohort Equations, High‐Sensitivity Troponin T, and N‐Terminal Pro–Brain‐Type Natriuretic Peptide for Predicting Atherosclerotic Cardiovascular Events Across the Spectrum of Kidney Dysfunction

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background Contemporary guidelines recommend using atherosclerotic cardiovascular disease screening tools to guide primary prevention. The performance of these scores is not well known in patients with moderate to advanced chronic kidney disease ...
Benjamin Lidgard, Leila R. Zelnick, Alan Go, Kevin D. O’Brien, Nisha Bansal   +4 more
doaj   +1 more source

Effect of DFPP on Ferroptosis in Peripheral Blood CD14+ Monocytes of Hyperlipidemic Patients Involving the ACSL4/LPCAT3/ALOX5 Pathway

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Introduction Hyperlipidemia is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). Although statins are the cornerstone of lipid‐lowering therapy, their use may be limited in some patients by adverse effects. This study evaluated the possible impact of non‐drug treatment using double‐filtration plasmapheresis (DFPP) on CD14+
Yun Cheng, Lan Li, Qingmei Yang, Meipeng Wu   +3 more
wiley   +1 more source

The Global Epidemic of Atherosclerotic Cardiovascular Disease [PDF]

Medical Principles and Practice, 2002
Of the 50 million deaths that occur in the world, 40 million occur in developing countries. Already a substantial proportion of these deaths are due to cardiovascular diseases. It is projected that by the year 2025 well over 80–90% of all the cardiovascular diseases in the world will be occurring in low income and middle income countries. This increase
Salim, Yusuf, Stephanie, Ounpuu, Sonia, Anand   +2 more
openaire   +2 more sources

Gut microbiome and aging—A dynamic interplay of microbes, metabolites, and the immune system

FEBS Letters, EarlyView.
Age‐dependent shifts in microbial communities engender shifts in microbial metabolite profiles. These in turn drive shifts in barrier surface permeability of the gut and brain and induce immune activation. When paired with preexisting age‐related chronic inflammation this increases the risk of neuroinflammation and neurodegenerative diseases.
Aaron Mehl, Eran Blacher
wiley   +1 more source

The Evolving Understanding and Approach to Residual Cardiovascular Risk Management

Frontiers in Cardiovascular Medicine, 2020
Despite unprecedented advances in treatment of atherosclerotic cardiovascular disease, it remains the leading cause of death and disability worldwide. Treatment of major traditional risk factors, including low-density lipoprotein-cholesterol, serves as ...
Devinder S. Dhindsa, Pratik B. Sandesara, Michael D. Shapiro, Nathan D. Wong   +3 more
doaj   +1 more source

Chelation therapy for atherosclerotic cardiovascular disease

Cochrane Database of Systematic Reviews, 2020
Chelation therapy is promoted and practiced around the world as a form of alternative medicine in the treatment of atherosclerotic cardiovascular disease. It has been suggested as a safe, relatively inexpensive, non-surgical method of restoring blood flow in atherosclerotic vessels.
Maria Vanessa, Villarruz-Sulit, Rachel, Forster, Antonio L, Dans, Flordeliza N, Tan, Dennis V, Sulit   +4 more
openaire   +3 more sources

Partial depletion of plasminogen activator inhibitor‐1 decreases subcutaneous fat cell hypertrophy and liver cholesterol in high‐fat‐fed female mice

FEBS Letters, EarlyView.
Obesity raises blood levels of PAI‐1, a protein linked to metabolic dysfunction‐associated steatotic liver disease in people with obesity. In female mice fed a high‐fat diet, partially lowering PAI‐1 led to smaller subcutaneous fat cells and lower liver cholesterol, without changing body weight or insulin sensitivity.
Claudia E. Ramirez Bustamante, Robert Sharp, Pradip K. Saha, Elizabeth S. Anaya, Elizabeth L. Lieu, Evelyn L. de Groot, Pooja Patel, Mi Jeong Heo, Aaron R. Cox, Kang Ho Kim, Sean M. Hartig   +10 more
wiley   +1 more source

10-YEAR RISK ESTIMATION OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE IN HYPERTENSIVE PATIENTS

Східноукраїнський медичний журнал, 2021
Introduction. Arterial hypertension is one of the most common causes of atherosclerotic cardiovascular disease, which is still the reason of mortality for a lot of persons.
Olha M. Chernatska, Xaba Sibongumusa
doaj   +1 more source